Search

Your search keyword '"Gónzalez-García, Andrés"' showing total 23 results
Start Over Author "Gónzalez-García, Andrés"
23 results on '"Gónzalez-García, Andrés"'

3. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study

Author

Arends, S., Treppo, E., Longhino, S., Manfrè, V., Rizzo, M., Baldini, C., Bombardieri, S., Bandeira, M., Silvéiro-António, M., Seror, R., Mariette, X., Nordmark, G., Danda, D., Wiland, P., Gerli, R., Kwok, S.K., Park, S.H., Kvarnstrom, M., Wahren-Herlenius, M., Downie-Doyle, S., Sene, D., Isenberg, D., Valim, V., Devauchelle-Pensec, V., Saraux, A., Morel, J., Morcillo, C., Díaz Cuiza, P.E., Herrera, B.E., González-de-Paz, L., Sisó-Almirall, A., Brito-Zerón, Pilar, Flores-Chávez, Alejandra, Horváth, Ildiko Fanny, Rasmussen, Astrid, Li, Xiaomei, Olsson, Peter, Vissink, Arjan, Priori, Roberta, Armagan, Berkan, Hernandez-Molina, Gabriela, Praprotnik, Sonja, Quartuccio, Luca, Inanç, Nevsun, Özkızıltaş, Burcugül, Bartoloni, Elena, Sebastian, Agata, Romão, Vasco C., Solans, Roser, Pasoto, Sandra G., Rischmueller, Maureen, Galisteo, Carlos, Suzuki, Yasunori, Trevisani, Virginia Fernandes Moça, Fugmann, Cecilia, González-García, Andrés, Carubbi, Francesco, Jurcut, Ciprian, Shimizu, Toshimasa, Retamozo, Soledad, Atzeni, Fabiola, Hofauer, Benedikt, Melchor-Díaz, Sheila, Gheita, Tamer, López-Dupla, Miguel, Fonseca-Aizpuru, Eva, Giacomelli, Roberto, Vázquez, Marcos, Consani, Sandra, Akasbi, Miriam, Nakamura, Hideki, Szántó, Antónia, Farris, A. Darise, Wang, Li, Mandl, Thomas, Gattamelata, Angelica, Kilic, Levent, Pirkmajer, Katja Perdan, Abacar, Kerem, Tufan, Abdurrahman, de Vita, Salvatore, Bootsma, Hendrika, and Ramos-Casals, Manuel

Published
2023
Full Text
View/download PDF

5. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)

Author

Carbonell, Cristina, Marcos, Miguel, Guillén-del-Castillo, Alfredo, Rubio-Rivas, Manuel, Argibay, Ana, Marín-Ballvé, Adela, Rodríguez-Pintó, Ignasi, Baldà-Masmiquel, Maria, Callejas-Moraga, Eduardo, Colunga, Dolores, Sáez-Comet, Luis, González-Echávarri, Cristina, Ortego-Centeno, Norberto, Marí-Alfonso, Begoña, Vargas-Hitos, José-Antonio, Todolí-Parra, José-Antonio, Trapiella, Luis, Herranz-Marín, María-Teresa, Freire, Mayka, Castro-Salomó, Antoni, Perales-Fraile, Isabel, Madroñero-Vuelta, Ana-Belén, Sánchez-García, María-Esther, Ruiz-Muñoz, Manuel, González-García, Andrés, Sánchez-Redondo, Jorge, de-la-Red-Bellvis, Gloria, Fernández-Luque, Alejandra, Muela-Molinero, Alberto, Lledó, Gema-María, Tolosa-Vilella, Carles, Fonollosa-Pla, Vicent, Chamorro, Antonio-Javier, and Simeón-Aznar, Carmen-Pilar

Published
2022
Full Text
View/download PDF

7. Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients

Author

De-Escalante, B., Chara-Cervantes, J., Pérez-Conesa, M., Rascón, J., Pallarés, L., Perez-Guerrero, P., De-la-Red, G., Calvo, E., Soler, C., Peral-Gutiérrez, E., Gómez-Cerezo, J.F., Rodríguez-Fernández, S., Pinilla, B., Toledo-Samaniego, N., Gato, A., Chamorro, A.J., Morcillo, C., Ojeda, I., Vives, M.J., de-Miguel, B., Penadés, M., De-Vicente, M., Brito-Zerón, Pilar, Pérez-Alvarez, Roberto, Feijoo-Massó, Carles, Gracia-Tello, Borja, González-García, Andres, Gómez-de-la-Torre, Ricardo, Alguacil, Ana, López-Dupla, Miguel, Robles, Angel, Garcia-Morillo, Salvador, Bonet, Mariona, Cruz-Caparrós, Gracia, Fonseca-Aizpuru, Eva, Akasbi, Miriam, Callejas, Jose Luis, de Miguel-Campo, Borja, Pérez-de-Lis, Marta, and Ramos-Casals, Manuel

Published
2021
Full Text
View/download PDF

10. Necrobiosis lipoidica

Author

Grillo, Emiliano, Gonzalez-Garcia, Andres, Jaen, Pedro, and Rodriguez-Munoz, Daniel

Published
2014

12. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.

Author

Caricchio, Roberto, Abbate, Antonio, Gordeev, Ivan, Meng, Jamie, Hsue, Priscilla Y, Neogi, Tuhina, Arduino, Roberto, Fomina, Daria, Bogdanov, Roman, Stepanenko, Tatiana, Ruiz-Seco, Pilar, Gónzalez-García, Andrés, Chen, Yu, Li, Yuhan, Whelan, Sarah, Noviello, Stephanie, and CAN-COVID Investigators

Subjects
PLACEBOS, ARTIFICIAL respiration, RESPIRATORY therapy, COVID-19 pandemic, RANDOMIZED controlled trials
Abstract

Importance: Effective treatments for patients with severe COVID-19 are needed.Objective: To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19.Design, Setting, and Participants: This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020.Intervention: Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227).Main Outcomes and Measures: The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations.Results: Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo.Conclusions and Relevance: Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29.Trial Registration: ClinicalTrials.gov Identifier: NCT04362813. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results